Caffeine Regulates Alternative Splicing in a Subset of Cancer-Associated Genes: a Role for SC35

REFERENCES

• Brinkman, B. M. 2004. Splice variants as cancer biomarkers. Clin. Biochem. 37:584–594.
   PubMed Web of Science ®Google Scholar
• Caceres, J. F., T. Misteli, G. R. Screaton, D. L. Spector, and A. R. Krainer. 1997. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J. Cell Biol. 138:225–238.
   PubMed Web of Science ®Google Scholar
• Caputi, M., and A. M. Zahler. 2002. SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. EMBO J. 21:845–855.
   PubMed Web of Science ®Google Scholar
• Carter, M. S., J. Doskow, P. Morris, S. Li, R. P. Nhim, S. Sandstedt, and M. F. Wilkinson. 1995. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J. Biol. Chem. 270:28995–29003.
   PubMed Web of Science ®Google Scholar
• Cho, Y. G., B. J. Choi, J. W. Song, S. Y. Kim, S. W. Nam, S. H. Lee, N. J. Yoo, J. Y. Lee, and W. S. Park. 2006. Aberrant expression of krüppel-like factor 6 protein in colorectal cancers. World J. Gastroenterol. 12:2250–2253.
   PubMedGoogle Scholar
• Chou, M. Y., N. Rooke, C. W. Turck, and D. L. Black. 1999. hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells. Mol. Cell. Biol. 19:69–77.
   PubMed Web of Science ®Google Scholar
• Dominski, Z., and R. Kole. 1991. Selection of splice sites in pre-mRNAs with short internal exons. Mol. Cell. Biol. 11:6075–6083.
   PubMed Web of Science ®Google Scholar
• Ebbinghaus, C., J. Scheuermann, D. Neri, and G. Elia. 2004. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr. Pharm. Des. 10:1537–1549.
   PubMed Web of Science ®Google Scholar
• Eperon, I. C., O. V. Makarova, A. Mayeda, S. H. Munroe, J. F. Caceres, D. G. Hayward, and A. R. Krainer. 2000. Selection of alternative 5′ splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20:8303–8318.
   PubMedGoogle Scholar
• Fairbrother, W. G., and L. A. Chasin. 2000. Human genomic sequences that inhibit splicing. Mol. Cell. Biol. 20:6816–6825.
   PubMed Web of Science ®Google Scholar
• Fischer, D. C., K. Noack, I. B. Runnebaum, D. O. Watermann, D. G. Kieback, S. Stamm, and E. Stickeler. 2004. Expression of splicing factors in human ovarian cancer. Oncol. Rep. 11:1085–1090.
   PubMed Web of Science ®Google Scholar
• Fu, X. D., and T. Maniatis. 1990. Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature 343:437–441.
   PubMed Web of Science ®Google Scholar
• Fu, X. D., A. Mayeda, T. Maniatis, and A. R. Krainer. 1992. General splicing factors SF2 and SC35 have equivalent activities in vitro, and both affect alternative 5′ and 3′ splice site selection. Proc. Natl. Acad. Sci. USA 89:11224–11228.
   PubMed Web of Science ®Google Scholar
• Graveley, B. R. 2000. Sorting out the complexity of SR protein functions. RNA 6:1197–1211.
   PubMed Web of Science ®Google Scholar
• Hanamura, A., J. F. Caceres, A. Mayeda, B. R. Franza, Jr., and A. R. Krainer. 1998. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430–444.
   PubMed Web of Science ®Google Scholar
• Hui, J., L. H. Hung, M. Heiner, S. Schreiner, N. Neumuller, G. Reither, S. A. Haas, and A. Bindereif. 2005. Intronic CA-repeat and CA-rich elements: a new class of regulators of mammalian alternative splicing. EMBO J. 24:1988–1998.
   PubMed Web of Science ®Google Scholar
• Hui, L., X. Zhang, X. Wu, Z. Lin, Q. Wang, Y. Li, and G. Hu. 2004. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 23:3013–3023.
   PubMedGoogle Scholar
• Ibrahim E. C., T. D. Schaal, K. J. Hertel, R. Reed, and T. Maniatis. 2005. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc. Natl. Acad. Sci. USA 102:5002–5007.
   PubMedGoogle Scholar
• Ito, G., M. Uchiyama, M. Kondo, S. Mori, N. Usami, O. Maeda, T. Kawabe, Y. Hasegawa, K. Shimokata, and Y. Sekido. 2004. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 64:3838–3843.
   PubMed Web of Science ®Google Scholar
• Jeng, Y. M., and H. C. Hsu. 2003. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int. J. Cancer 105:625–629.
   PubMedGoogle Scholar
• Jin, S., and K. W. Scotto. 1998. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18:4377–4384.
   PubMed Web of Science ®Google Scholar
• Kalnina, Z., P. Zayakin, K. Silina, and A. Line. 2005. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342–357.
   PubMedGoogle Scholar
• Karni, R., E. de Stanchina, S. W. Lowe, R. Sinha, D. Mu, and A. R. Krainer. 2007. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14:185–193.
   PubMed Web of Science ®Google Scholar
• Kessler, K. R., and R. Benecke. 1997. The EBD test: a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord. 12:95–99.
   PubMed Web of Science ®Google Scholar
• Kim, S., H. Shi, D. K. Lee, and J. T. Lis. 2003. Specific SR protein-dependent splicing substrates identified through genomic SELEX. Nucleic Acids Res. 31:1955–1961.
   PubMed Web of Science ®Google Scholar
• Kimmelman, A. C., R. F. Qiao, G. Narla, A. Banno, N. Lau, P. D. Bos, N. Nunez Rodriguez, B. C. Liang, A. Guha, J. A. Martignetti, S. L. Friedman, and A. M. Chan. 2004. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23:5077–5083.
   PubMedGoogle Scholar
• Kirschbaum-Slager, N., G. M. Lopes, P. A. Galante, G. J. Riggins, and S. J. de Souza. 2004. Splicing factors are differentially expressed in tumors. Genet. Mol. Res. 3:512–520.
   PubMedGoogle Scholar
• Lin, S., R. Xiao, P. Sun, X. Xu, and X. D. Fu. 2005. Dephosphorylation-dependent sorting of SR splicing factors during mRNP maturation. Mol. Cell 20:413–425.
   PubMed Web of Science ®Google Scholar
• Liu, H. X., S. L. Chew, L. Cartegni, M. Q. Zhang, and A. R. Krainer. 2000. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 20:1063–1071.
   PubMed Web of Science ®Google Scholar
• Maeda, T., and S. Furukawa. 2001. Transformation-associated changes in gene expression of alternative splicing regulatory factors in mouse fibroblast cells. Oncol. Rep. 8:563–566.
   PubMedGoogle Scholar
• Manley, J. L., and R. Tacke. 1996. SR proteins and splicing control. Genes Dev. 10:1569–1579.
   PubMed Web of Science ®Google Scholar
• Matlin, A. J., F. Clark, and C. W. Smith. 2005. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 6:386–398.
   PubMed Web of Science ®Google Scholar
• Mayeda, A., S. H. Munroe, J. F. Caceres, and A. R. Krainer. 1994. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13:5483–5495.
   PubMed Web of Science ®Google Scholar
• Modafferi, E. F., and D. L. Black. 1997. A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon. Mol. Cell. Biol. 17:6537–6545.
   PubMedGoogle Scholar
• Modrek, B., and C. J. Lee. 2003. Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat. Genet. 34:177–180.
   PubMed Web of Science ®Google Scholar
• Modrek, B., A. Resch, C. Grasso, and C. Lee. 2001. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29:2850–2859.
   PubMed Web of Science ®Google Scholar
• Nagy, E., and L. E. Maquat. 1998. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23:198–199.
   PubMed Web of Science ®Google Scholar
• Narla, G., A. Difeo, H. L. Reeves, D. J. Schaid, J. Hirshfeld, E. Hod, A. Katz, W. B. Isaacs, S. Hebbring, A. Komiya, S. K. McDonnell, K. E. Wiley, S. J. Jacobsen, S. D. Isaacs, P. C. Walsh, S. L. Zheng, B. L. Chang, D. M. Friedrichsen, J. L. Stanford, E. A. Ostrander, A. M. Chinnaiyan, M. A. Rubin, J. Xu, S. N. Thibodeau, S. L. Friedman, and J. A. Martignetti. 2005. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65:1213–1222.
   PubMed Web of Science ®Google Scholar
• Narla, G., A. DiFeo, S. Yao, A. Banno, E. Hod, H. L. Reeves, R. F. Qiao, O. Camacho-Vanegas, A. Levine, A. Kirschenbaum, A. M. Chan, S. L. Friedman, and J. A. Martignetti. 2005. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65:5761–5768.
   PubMed Web of Science ®Google Scholar
• Narla, G., K. E. Heath, H. L. Reeves, D. Li, L. E. Giono, A. C. Kimmelman, M. J. Glucksman, J. Narla, F. J. Eng, A. M. Chan, A. C. Ferrari, J. A. Martignetti, and S. L. Friedman. 2001. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294:2563–2566.
   PubMed Web of Science ®Google Scholar
• Narla, G., S. Kremer-Tal, N. Matsumoto, X. Zhao, S. Yao, K. Kelley, M. Tarocchi, and S. L. Friedman. 2007. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26:4428–4434.
   PubMedGoogle Scholar
• Noonan, K. E., C. Beck, T. A. Holzmayer, J. E. Chin, J. S. Wunder, I. L. Andrulis, A. F. Gazdar, C. L. Willman, B. Griffith, D. D. Von Hoff, et al. 1990. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:7160–7164.
   PubMed Web of Science ®Google Scholar
• Ohler, U., N. Shomron, and C. B. Burge. 2005. Recognition of unknown conserved alternatively spliced exons. PLoS Comput. Biol. 1:113–122.
   PubMedGoogle Scholar
• Pan, X. C., Z. Chen, F. Chen, X. H. Chen, C. Zhou, and Z. G. Yang. 2006. Mutations of the tumor suppressor Kruppel-like factor 6 (KLF6) gene in hepatocellular carcinoma and its effect of growth suppression on human hepatocellular carcinoma cell line HepG2. Zhonghua Gan Zang Bing Za Zhi 14:109-113. (In Chinese.)
   PubMedGoogle Scholar
• Reeves, H. L., G. Narla, O. Ogunbiyi, A. I. Haq, A. Katz, S. Benzeno, E. Hod, N. Harpaz, S. Goldberg, S. Tal-Kremer, F. J. Eng, M. J. Arthur, J. A. Martignetti, and S. L. Friedman. 2004. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126:1090–1103.
   PubMed Web of Science ®Google Scholar
• Sadusky, T., A. J. Newman, and N. J. Dibb. 2004. Exon junction sequences as cryptic splice sites: implications for intron origin. Curr. Biol. 14:505–509.
   PubMedGoogle Scholar
• Smid-Koopman, E., L. J. Blok, T. J. Helmerhorst, S. Chadha-Ajwani, C. W. Burger, A. O. Brinkmann, and F. J. Huikeshoven. 2004. Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. Gynecol. Oncol. 93:292–300.
   PubMedGoogle Scholar
• Spellman, R., A. Rideau, A. Matlin, C. Gooding, F. Robinson, N. McGlincy, S. N. Grellscheid, J. Southby, M. Wollerton, and C. W. Smith. 2005. Regulation of alternative splicing by PTB and associated factors. Biochem. Soc. Trans. 33:457–460.
   PubMed Web of Science ®Google Scholar
• Tacke, R., and J. L. Manley. 1995. The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J. 14:3540–3551.
   PubMed Web of Science ®Google Scholar
• Usuki, F., A. Yamashita, I. Higuchi, T. Ohnishi, T. Shiraishi, M. Osame, and S. Ohno. 2004. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann. Neurol. 55:740–744.
   PubMed Web of Science ®Google Scholar
• Venables, J. P. 2004. Aberrant and alternative splicing in cancer. Cancer Res. 64:7647–7654.
   PubMed Web of Science ®Google Scholar
• Venables, J. P. 2006. Unbalanced alternative splicing and its significance in cancer. Bioessays 28:378–386.
   PubMed Web of Science ®Google Scholar
• Wang, Z., H. S. Lo, H. Yang, S. Gere, Y. Hu, K. H. Buetow, and M. P. Lee. 2003. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 63:655–657.
   PubMedGoogle Scholar
• Wang, Z., M. E. Rolish, G. Yeo, V. Tung, M. Mawson, and C. B. Burge. 2004. Systematic identification and analysis of exonic splicing silencers. Cell 119:831–845.
   PubMed Web of Science ®Google Scholar
• Wang, Z., X. Xiao, E. Van Nostrand, and C. B. Burge. 2006. General and specific functions of exonic splicing silencers in splicing control. Mol. Cell 23:61–70.
   PubMed Web of Science ®Google Scholar
• Watakabe, A., K. Tanaka, and Y. Shimura. 1993. The role of exon sequences in splice site selection. Genes Dev. 7:407–418.
   PubMed Web of Science ®Google Scholar
• Xu, Q., and C. Lee. 2003. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 31:5635–5643.
   PubMed Web of Science ®Google Scholar
• Zhu, J., A. Mayeda, and A. R. Krainer. 2001. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell 8:1351–1361.
   PubMedGoogle Scholar